gastrointestinal cancers
Recently Published Documents


TOTAL DOCUMENTS

1393
(FIVE YEARS 689)

H-INDEX

48
(FIVE YEARS 22)

2022 ◽  
Vol 23 (2) ◽  
pp. 930
Author(s):  
Ba Da Yun ◽  
Ye Ji Choi ◽  
Seung Wan Son ◽  
Gabriel Adelman Cipolla ◽  
Fernanda Costa Brandão Berti ◽  
...  

Circular RNAs (circRNAs) and long noncoding RNAs (lncRNAs) are differentially expressed in gastrointestinal cancers. These noncoding RNAs (ncRNAs) regulate a variety of cellular activities by physically interacting with microRNAs and proteins and altering their activity. It has also been suggested that exosomes encapsulate circRNAs and lncRNAs in cancer cells. Exosomes are then discharged into the extracellular environment, where they are taken up by other cells. As a result, exosomal ncRNA cargo is critical for cell–cell communication within the cancer microenvironment. Exosomal ncRNAs can regulate a range of events, such as angiogenesis, metastasis, immune evasion, drug resistance, and epithelial-to-mesenchymal transition. To set the groundwork for developing novel therapeutic strategies against gastrointestinal malignancies, a thorough understanding of circRNAs and lncRNAs is required. In this review, we discuss the function and intrinsic features of oncogenic circRNAs and lncRNAs that are enriched within exosomes.


2022 ◽  
Vol 14 (1) ◽  
pp. 75-89
Author(s):  
Hui-Yan Sun ◽  
Song-Tao Du ◽  
Ya-Yun Li ◽  
Guang-Tong Deng ◽  
Fu-Rong Zeng

Author(s):  
Abdulrahman Ali Alzandi ◽  
Essam Ahmed Taher ◽  
Mohamed Azizi ◽  
Nageeb A. Al-Sagheer ◽  
Abdul Wali Al-Khulaidi ◽  
...  

2022 ◽  
pp. 114907
Author(s):  
Tao Su ◽  
Teng Wang ◽  
Nasha Zhang ◽  
Yue Shen ◽  
Wenwen Li ◽  
...  

2022 ◽  
Vol 145 ◽  
pp. 112394
Author(s):  
Afsane Bahrami ◽  
Amirsajad Jafari ◽  
Gordon A. Ferns

2022 ◽  
Vol 21 ◽  
pp. 153473542110674
Author(s):  
Sierra J. McDonald ◽  
Brandon N. VanderVeen ◽  
Kandy T. Velazquez ◽  
Reilly T. Enos ◽  
Ciaran M. Fairman ◽  
...  

Gastrointestinal (GI) cancers cause one-third of all cancer-related deaths worldwide. Natural compounds are emerging as alternative or adjuvant cancer therapies given their distinct advantage of manipulating multiple pathways to both suppress tumor growth and alleviate cancer comorbidities; however, concerns regarding efficacy, bioavailability, and safety are barriers to their development for clinical use. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a Chinese herb-derived anthraquinone, has been shown to exert anti-tumor effects in colon, liver, and pancreatic cancers. While the mechanisms underlying emodin’s tumoricidal effects continue to be unearthed, recent evidence highlights a role for mitochondrial mediated apoptosis, modulated stress and inflammatory signaling pathways, and blunted angiogenesis. The goals of this review are to (1) highlight emodin’s anti-cancer properties within GI cancers, (2) discuss the known anti-cancer mechanisms of action of emodin, (3) address emodin’s potential as a treatment complementary to standard chemotherapeutics, (4) assess the efficacy and bioavailability of emodin derivatives as they relate to cancer, and (5) evaluate the safety of emodin.


Sign in / Sign up

Export Citation Format

Share Document